title: S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: a microdialysis study.
abstract: Disulfiram (DSF), used for the treatment of alcohol use disorders (AUDs) for over six decades, most recently has shown promise for treating cocaine dependence. Although DSF's mechanism of action in alcohol abuse is due to the inhibition of liver mitochondrial aldehyde dehydrogenase (ALDH2), its mechanism of action in the treatment of cocaine dependence is unknown. DSF is a pro-drug, forming a number of metabolites each with discrete pharmacological actions. One metabolite formed during DSF bioactivation is S-(N, N-diethylcarbamoyl) glutathione (carbamathione) (carb). We previously showed that carb affects glutamate binding. In the present studies, we employed microdialysis techniques to investigate the effect of carb administration on dopamine (DA), GABA, and glutamate (Glu) in the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), two brain regions implicated in substance abuse dependence. The effect of DSF on DA, GABA, and Glu in the NAc also was determined. Both studies were carried out in male rats. Carb (20, 50, 200 mg/kg i v) in a dose-dependent manner increased DA, decreased GABA, and had a biphasic effect on Glu, first increasing and then decreasing Glu in both the NAc and mPFC. These changes all occurred concurrently. After carb administration, NAc and mPFC carb, as well as carb in plasma, were rapidly eliminated with a half-life for each approximately 4 min, while the changes in DA, GABA, and GLu in the NAc and mPFC persisted for approximately two hours. The maximal increase in carb (Cmax) in the NAc and mPFC after carb administration was dose-dependent, as was the area under the curve (AUC). DSF (200 mg/kg i p) also increased DA, decreased GABA, and had a biphasic effect on Glu in the NAc similar to that observed in the NAc after carb administration. When the cytochrome P450 inhibitor N-benzylimidazole (NBI) (20 mg/kg i p) was administered before DSF dosing, no carb could be detected in the NAc and plasma and also no changes in NAc DA, GABA, and GLu occurred. Changes in these neurotransmitters occurred only if carb was formed from DSF. When NBI was administered prior to dosing with carb, the increase in DA, decrease in GABA, and biphasic effect on GLu was similar to that seen after dosing with carb only. The i p or i v administration of carb showed similar changes in DA, GABA, and GLu, except the time to reach Cmax for DA as well as the changes in GABA, and GLu after i p administration occurred later. The elimination half-life of carb and the area under the curve (AUC) were similar after both routes of administration. It is concluded that carb must be formed from DSF before any changes in DA, GABA, and GLu in the NAc and mPFC are observed. DSF and carb, when administered to rats, co-release DA, GABA, and GLu. Carb, once formed can cross the blood brain barrier and enter the brain. Although inhibition of liver ALDH2 is the accepted mechanism for DSF's action in treating AUDs, the concurrent changes in DA, GABA, and GLu in the NAc and mPFC after DSF administration suggest that changes in these neurotransmitters as a potential mechanism of action not only for AUDs, but also for cocaine dependence cannot be excluded.
authors.affiliation: Department of Pharmacology and Toxicology, University of Kansas, Lawrence, KS 66045, USA. Electronic address: mfaiman@ku.edu.
authors.forename: Morris D
authors.initials: MD
authors.lastname: Faiman
authors.affiliation: Department of Chemistry, University of Kansas, Lawrence, KS 66045, USA.
authors.forename: Swetha
authors.initials: S
authors.lastname: Kaul
authors.affiliation: Department of Pharmacology and Toxicology, University of Kansas, Lawrence, KS 66045, USA. Electronic address: ShaheenLatif@gmail.com.
authors.forename: Shaheen A
authors.initials: SA
authors.lastname: Latif
authors.affiliation: Department of Medicinal Chemistry, University of Kansas, Lawrence, KS 66045, USA.
authors.forename: Todd D
authors.initials: TD
authors.lastname: Williams
authors.affiliation: Department of Chemistry, University of Kansas, Lawrence, KS 66045, USA.
authors.forename: Craig E
authors.initials: CE
authors.lastname: Lunte
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D018698:Glutamic Acid / Q000378:metabolism*; D005978:Glutathione / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D017551:Microdialysis; D009714:Nucleus Accumbens / Q000187:drug effects* / Q000378:metabolism; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: D000317:Adrenergic alpha-Antagonists; D007093:Imidazoles; C546728:carbamathione; D018698:Glutamic Acid; C017062:1-benzylimidazole; D005680:gamma-Aminobutyric Acid; D005978:Glutathione; D004298:Dopamine
keywords: Carbamathione; Disulfiram; Dopamine; GABA; Glutamate; Microdialysis
references.citation: Curr Psychiatry Rep. 2010 Oct;12(5):441-7
references.pmid: 20697850
references.citation: Recent Pat CNS Drug Discov. 2011 May 1;6(2):146-60
references.pmid: 21599628
references.citation: Biochem Pharmacol. 1991 Sep 12;42(7):1361-6
references.pmid: 1656985
references.citation: Alcohol Clin Exp Res. 2006 Sep;30(9):1451-65
references.pmid: 16930207
references.citation: Addiction. 1998 May;93(5):713-27
references.pmid: 9692270
references.citation: Ann N Y Acad Sci. 2003 Nov;1003:36-52
references.pmid: 14684434
references.citation: Biochem Pharmacol. 1993 Dec 14;46(12):2285-90
references.pmid: 8274162
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):119-25
references.pmid: 12595952
references.citation: Synapse. 1996 Oct;24(2):165-72
references.pmid: 8890458
references.citation: J Pharmacol Exp Ther. 1995 Feb;272(2):775-80
references.pmid: 7853193
references.citation: Eur J Pharmacol. 2001 Mar 2;414(2-3):205-9
references.pmid: 11239920
references.citation: Neuropsychopharmacology. 2007 Mar;32(3):719-27
references.pmid: 16525415
references.citation: Drug Metab Dispos. 1995 Oct;23(10):1153-62
references.pmid: 8654205
references.citation: Drug Metab Dispos. 1994 Mar-Apr;22(2):324-30
references.pmid: 8013289
references.citation: Synapse. 1998 Oct;30(2):119-29
references.pmid: 9723781
references.citation: Biochem Pharmacol. 1989 Feb 1;38(3):413-21
references.pmid: 2537080
references.citation: Eur J Pharmacol. 1990 Oct 23;187(3):555-6
references.pmid: 2150045
references.citation: J Biol Chem. 1997 Sep 26;272(39):24247-51
references.pmid: 9305877
references.citation: Brain Res Bull. 2002 Mar 15;57(5):623-30
references.pmid: 11927365
references.citation: Neuropsychopharmacology. 2010 Nov;35(12):2440-9
references.pmid: 20736996
references.citation: Mol Pharmacol. 1994 Dec;46(6):1217-25
references.pmid: 7808445
references.citation: Trends Pharmacol Sci. 2008 Mar;29(3):109-15
references.pmid: 18262663
references.citation: Biochem Pharmacol. 1993 Dec 14;46(12):2291-7
references.pmid: 8274163
references.citation: Toxicol Appl Pharmacol. 1996 Jul;139(1):102-8
references.pmid: 8685891
references.citation: Biochem Pharmacol. 1963 Feb;12:157-66
references.pmid: 13978937
references.citation: J Psychiatry Neurosci. 2004 Jul;29(4):296-310
references.pmid: 15309046
references.citation: Lancet. 1948 Dec 25;2(6539):1001-4
references.pmid: 18103475
references.citation: Toxicol Appl Pharmacol. 1993 Jun;120(2):186-92
references.pmid: 8511787
references.citation: Addict Biol. 2007 Jun;12(2):133-51
references.pmid: 17508985
references.citation: Addiction. 2000 Feb;95(2):219-28
references.pmid: 10723850
references.citation: J Med Chem. 2012 Jan 12;55(1):357-66
references.pmid: 22128851
references.citation: Alcohol Clin Exp Res. 1998 Sep;22(6):1212-9
references.pmid: 9756035
references.citation: Am J Addict. 2007 Mar-Apr;16(2):71-8
references.pmid: 17453607
references.citation: Neurosci Biobehav Rev. 2006;30(2):215-38
references.pmid: 16099045
references.citation: Pharmacol Biochem Behav. 2008 Jun;89(4):556-62
references.pmid: 18329701
references.citation: Addiction. 2000 Sep;95(9):1335-49
references.pmid: 11048353
references.citation: J Pharm Biomed Anal. 2010 Jan 5;51(1):186-91
references.pmid: 19709836
references.citation: Biol Psychiatry. 2000 Jun 15;47(12):1080-6
references.pmid: 10862808
references.citation: Biochem Pharmacol. 1972 Jan 15;21(2):219-30
references.pmid: 4645555
references.citation: J Chromatogr. 1990 Dec 14;534:57-66
references.pmid: 1965596
references.citation: Acta Psychiatr Scand Suppl. 1992;369:15-26
references.pmid: 1471547
references.citation: Pharmacol Ther. 2005 Oct;108(1):94-108
references.pmid: 16083966
references.citation: J Neurosci. 2001 Nov 1;21(21):8655-63
references.pmid: 11606653
references.citation: Mol Psychiatry. 2003 Apr;8(4):373-82
references.pmid: 12740594
references.citation: Mini Rev Med Chem. 2012 Oct;12(12):1202-15
references.pmid: 22931592
references.citation: Biochem Pharmacol. 2008 Jan 1;75(1):218-65
references.pmid: 17706608
references.citation: Life Sci (1962). 1964 Jul;3:763-7
references.pmid: 14203977
references.citation: J Neurosci. 1997 Apr 15;17(8):2921-7
references.pmid: 9092613
references.citation: Synapse. 1998 Jan;28(1):60-5
references.pmid: 9414018
references.citation: Chem Res Toxicol. 1994 Jul-Aug;7(4):526-33
references.pmid: 7981417
references.citation: Psychopharmacology (Berl). 2012 Feb;219(4):1153-64
references.pmid: 21863234
references.citation: Arch Gen Psychiatry. 2004 Mar;61(3):264-72
references.pmid: 14993114
references.citation: CNS Neurol Disord Drug Targets. 2008 Nov;7(5):482-91
references.pmid: 19128205
references.citation: Pharmacol Biochem Behav. 2008 Aug;90(2):226-35
references.pmid: 18508116
references.citation: Mol Interv. 2009 Aug;9(4):175-87
references.pmid: 19720750
references.citation: Biochem Pharmacol. 1963 Jul;12:705-15
references.pmid: 13978936
references.citation: Biochem Pharmacol. 1992 Feb 4;43(3):403-6
references.pmid: 1311578
references.citation: Nat Med. 2010 Sep;16(9):1024-8
references.pmid: 20729865
references.citation: Clin Pharmacol Ther. 1984 Oct;36(4):520-6
references.pmid: 6090051
references.citation: BMC Med. 2011 Nov 03;9:119
references.pmid: 22047090
references.citation: J Pharmacol Exp Ther. 1993 Jan;264(1):289-93
references.pmid: 8093728
references.citation: Nature. 1985 Feb 7-13;313(6002):479-81
references.pmid: 2982106
references.citation: Alcohol Clin Exp Res. 1994 Aug;18(4):1013-7
references.pmid: 7978080
references.citation: J Pharmacol Exp Ther. 1998 Jun;285(3):961-7
references.pmid: 9618395
references.citation: Int J Neuropsychopharmacol. 2008 May;11(3):425-38
references.pmid: 17927843
references.citation: Electrophoresis. 2011 Jan;32(2):284-91
references.pmid: 21254127
references.citation: J Pharmacol Exp Ther. 1977 Sep;202(3):724-31
references.pmid: 197231
references.citation: Proc Assoc Am Physicians. 1999 Mar-Apr;111(2):99-108
references.pmid: 10220804
references.citation: Nat Neurosci. 2005 Feb;8(2):147-8
references.pmid: 15643429
references.citation: Neuroscience. 2003;117(3):697-706
references.pmid: 12617973
references.citation: Brain Res. 1990 Oct 22;530(2):223-8
references.pmid: 2176114
references.citation: J Neurosci. 1994 Jan;14(1):442-50
references.pmid: 8283249